Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study

Autor: Tomoo Fukuda, Keiko Yamagami, Kimito Kawahata, Yuzo Suzuki, Yoshihiro Sasaki, Takashi Miyagi, Iris Jacobs, John-Philip Lawo, Fiona Glassman, Hideto Akama, Michihiro Hide, Isao Ohsawa

Publikováno v: Allergology International, Vol 72, Iss 3, Pp 451-457 (2023)

Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by recurrent attacks of angioedema. HAE types I and II result from deficient or dysfunctional C1-esterase inhibitor (C1–INH). This Pha

Externí odkaz: https://doaj.org/article/41fb99ae42094f549215fbbd33660195

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Autor: William R. Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Aleena Banerji, Jonathan A. Bernstein, Teresa Caballero, Henriette Farkas, Richard G. Gower, Paul K. Keith, Donald S. Levy, H. Henry Li, Markus Magerl, Michael Manning, Marc A. Riedl, John-Philip Lawo, Subhransu Prusty, Thomas Machnig, Hilary Longhurst, on behalf of the COMPACT Investigators

Publikováno v: Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-14 (2021)

Abstract Background Long-term prophylaxis with subcutaneous C1-inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) in patients with hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE) was evaluated in an open-label extension follow-up study t

Externí odkaz: https://doaj.org/article/3d0ee6580c494bd3a3f9bff57e907f0f

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Autor: William R. Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Aleena Banerji, Jonathan A. Bernstein, Teresa Caballero, Henriette Farkas, Richard G. Gower, Paul K. Keith, Donald S. Levy, H. Henry Li, Markus Magerl, Michael Manning, Marc A. Riedl, John-Philip Lawo, Subhransu Prusty, Thomas Machnig, Hilary Longhurst, the COMPACT Investigators

Publikováno v: Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-2 (2021)

Externí odkaz: https://doaj.org/article/d80ded04a23e4f01b4918bb890575a6e

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

Autor: Theresa Yuraszeck, Michael A. Tortorici, Billie L. Durn, Hans-Peter Hartung, Orell Mielke, Vera Bril, Ivo N. van Schaik, David R. Cornblath, Marc Pfister, Gen Sobue, Ingemar S. J. Merkies, Xuewen Ma, Michaela Praus, John-Philip Lawo, Richard A. Lewis, Petra M. Jauslin

Publikováno v: CPT: Pharmacometrics and Systems Pharmacology, 10(8), 839-850. Wiley
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 839-850 (2021)

The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09b76a98d0b112baca25fdca06cf2202
https://doi.org/10.1002/psp4.12647

TH-120. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy

Autor: Monica Alcantara, Hans-Peter Hartung, John-Philip Lawo, Billie Durn, Orell Mielke, Vera Bril

Publikováno v: Clinical Neurophysiology. 141:S114-S115

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::58f655df31cb7b2b368165c87314adc6
https://doi.org/10.1016/j.clinph.2022.07.300